Literature DB >> 31175937

The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?

Houda Abla1, Manuela Sollazzo2, Giuseppe Gasparre3, Luisa Iommarini4, Anna Maria Porcelli5.   

Abstract

The thriving field that constitutes cancer metabolism has unveiled some groundbreaking facts over the past two decades, at the heart of which is the TCA cycle and its intermediates. As such and besides its metabolic role, α-ketoglutarate was shown to withstand a wide range of physiological reactions from protection against oxidative stress, collagen and bone maintenance to development and immunity. Most importantly, it constitutes the rate-limiting substrate of 2-oxoglutarate-dependent dioxygenases family enzymes, which are involved in hypoxia sensing and in the shaping of cellular epigenetic landscape, two major drivers of oncogenic transformation. Based on literature reports, we hereby review the benefits of this metabolite as a possible novel adjuvant therapeutic opportunity to target tumor progression. This article is part of the special issue "Mitochondrial metabolic alterations in cancer cells and related therapeutic targets".
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cancer metabolism; Drosophila melanogaster; Epigenetics; Hypoxia; Tumor progression; α-Ketoglutarate

Year:  2019        PMID: 31175937     DOI: 10.1016/j.semcdb.2019.05.031

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  19 in total

Review 1.  Targeting 2-oxoglutarate dehydrogenase for cancer treatment.

Authors:  Ling-Chu Chang; Shih-Kai Chiang; Shuen-Ei Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

2.  α-Ketoglutarate-Mediated DNA Demethylation Sustains T-Acute Lymphoblastic Leukemia upon TCA Cycle Targeting.

Authors:  Yanwu Wang; Ning Shen; Gervase Spurlin; Sovannarith Korm; Sarah Huang; Nicole M Anderson; Leah N Huiting; Hudan Liu; Hui Feng
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

Review 3.  Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.

Authors:  Teodoro Jerves; Nenad Blau; Carlos R Ferreira
Journal:  Mol Genet Metab       Date:  2022-03-28       Impact factor: 4.204

Review 4.  The functional roles of TCA cycle metabolites in cancer.

Authors:  Joseph Eniafe; Shuai Jiang
Journal:  Oncogene       Date:  2021-04-16       Impact factor: 9.867

Review 5.  Crucial Functions of the JMJD1/KDM3 Epigenetic Regulators in Cancer.

Authors:  Yuan Sui; Ruicai Gu; Ralf Janknecht
Journal:  Mol Cancer Res       Date:  2020-06-30       Impact factor: 6.333

Review 6.  IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives.

Authors:  Fabiana Crispo; Michele Pietrafesa; Valentina Condelli; Francesca Maddalena; Giuseppina Bruno; Annamaria Piscazzi; Alessandro Sgambato; Franca Esposito; Matteo Landriscina
Journal:  Molecules       Date:  2020-08-18       Impact factor: 4.411

Review 7.  Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.

Authors:  Livingstone Fultang; Luciana Gneo; Carmela De Santo; Francis J Mussai
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

Review 8.  Interfering with Tumor Hypoxia for Radiotherapy Optimization.

Authors:  Irma Telarovic; Roland H Wenger; Martin Pruschy
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21

Review 9.  Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies.

Authors:  Zhefang Wang; Fanyu Liu; Ningbo Fan; Chenghui Zhou; Dai Li; Thomas Macvicar; Qiongzhu Dong; Christiane J Bruns; Yue Zhao
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

Review 10.  Multifaceted role of branched-chain amino acid metabolism in cancer.

Authors:  Hui Peng; Yingfei Wang; Weibo Luo
Journal:  Oncogene       Date:  2020-09-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.